Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
World Journal of Surgery

01-11-2017 | Original Scientific Report

Prognostic Significance of Lymphocyte Counts in Colon Cancer Patients Treated with FOLFOX Chemotherapy

Authors: O Kyu Noh, Seung Yeop Oh, Young Bae Kim, Kwang Wook Suh

Published in: World Journal of Surgery | Issue 11/2017

Login to get access

Abstract

Purpose

There is increasing interest in immune function in combination with chemotherapy for cancer treatment. However, the effects of chemotherapy on the human immune system remain to be determined. The aim of this study was to investigate the prognostic impact of lymphocyte and neutrophil counts in colon cancer patients who were treated with curative surgery and adjuvant chemotherapy.

Methods

Two hundred thirty-one patients with colon cancers who underwent curative surgery and FOLFOX adjuvant chemotherapy between November 2005 and December 2011 were included. Oncologic outcomes were analyzed with neutrophil count, lymphocyte count, and neutrophil-to-lymphocyte ratio (NLR) before and after chemotherapy.

Results

The 5-year DFS rate was lower in colon cancer patients with low lymphocyte count during chemotherapy (61.9 vs. 76.7%, P = 0.026). Cox multivariate analysis demonstrated that low lymphocyte count during chemotherapy was independently associated with poor disease-free survival (HR 1.829; 95% CI 1.096–3.050; P = 0.021) in colon cancer patients who underwent FOLFOX adjuvant chemotherapy.

Conclusion

Lymphocyte count during chemotherapy is a strong predictor of worse disease-free survival in colon cancer patients who have undergone FOLFOX adjuvant chemotherapy.
Literature
1.
Hermanek P Jr, Wiebelt H, Riedl S, Staimmer D et al (1994) Long-term results of surgical therapy of colon cancer. Results of the Colorectal Cancer Study Group. Chirurg 65:287–297PubMed
2.
Andre T, Boni C, Mounedji-Boudiaf L et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343–2351CrossRefPubMed
3.
Nishijima TF, Muss HB, Shachar SS et al (2015) Prognostic value of lymphocyte-to-monocyte ratio in patients with solid tumors: a systematic review and meta-analysis. Cancer Treat Rev 41:971–978CrossRefPubMed
4.
Ray-Coquard I, Cropet C, Van Glabbeke M et al (2009) Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res 69:5383–5391CrossRefPubMedPubMedCentral
5.
Shin JS, Suh KW, Oh SY (2015) Preoperative neutrophil to lymphocyte ratio predicts survival in patients with T1-2N0 colorectal cancer. J Surg Oncol 112:654–657CrossRefPubMed
6.
Kitayama J, Yasuda K, Kawai K et al (2011) Circulating lymphocyte is an important determinant of the effectiveness of preoperative radiotherapy in advanced rectal cancer. BMC Cancer 11:1471–2407CrossRef
7.
Kitayama J, Yasuda K, Kawai K et al (2010) Circulating lymphocyte number has a positive association with tumor response in neoadjuvant chemoradiotherapy for advanced rectal cancer. Radiat Oncol 5:5–47CrossRef
8.
Ceze N, Thibault G, Goujon G et al (2011) Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy. Cancer Chemother Pharmacol 68:1305–1313CrossRefPubMed
9.
Chu-Yuan H, Jing P, Yi-Sheng W et al (2013) The impact of chemotherapy-associated neutrophil/lymphocyte counts on prognosis of adjuvant chemotherapy in colorectal cancer. BMC Cancer 13:1471–2407CrossRef
10.
Kobayashi N, Usui S, Kikuchi S et al (2012) Preoperative lymphocyte count is an independent prognostic factor in node-negative non-small cell lung cancer. Lung Cancer 75:223–227CrossRefPubMed
11.
12.
Clark EJ, Connor S, Taylor MA et al (2007) Preoperative lymphocyte count as a prognostic factor in resected pancreatic ductal adenocarcinoma. HPB 9:456–460CrossRefPubMedPubMedCentral
13.
Vicente Conesa MA, Garcia-Martinez E, Gonzalez Billalabeitia E et al (2012) Predictive value of peripheral blood lymphocyte count in breast cancer patients treated with primary chemotherapy. Breast 21:468–474CrossRefPubMed
14.
Sica A, Saccani A, Bottazzi B et al (2000) Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages. J Immunol 164:762–767CrossRefPubMed
15.
Formenti SC, Demaria S (2008) Effects of chemoradiation on tumor-host interactions: the immunologic side. J Clin Oncol 26:1562–1563 (author reply 1563) CrossRefPubMed
16.
Menard C, Martin F, Apetoh L et al (2008) Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunol Immunother 57:1579–1587CrossRefPubMed
17.
18.
Sakaguchi S, Yamaguchi T, Nomura T et al (2008) Regulatory T cells and immune tolerance. Cell 133:775–787CrossRefPubMed
19.
Sunaga T, Suzuki S, Kogo M et al (2014) The association between neutropenia and prognosis in stage III colorectal cancer patients receiving adjuvant chemotherapy. Eur J Cancer Care 23:394–400CrossRef
20.
McCoy MJ, Lake RA, van der Most RG et al (2012) Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies. Br J Cancer 107:1107–1115CrossRefPubMedPubMedCentral
21.
Tartour E, Blay JY, Dorval T et al (1996) Predictors of clinical response to interleukin-2-based immunotherapy in melanoma patients. J Clin Oncol 14:1697–1703CrossRefPubMed
22.
Mackall CL, Hakim FT, Gress RE (1997) Restoration of T-cell homeostasis after T-cell depletion. Semin Immunol 9:339–346CrossRefPubMed
23.
Schluns KS, Kieper WC, Jameson SC et al (2000) Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat Immunol 1:426–432CrossRefPubMed
24.
Tan JT, Ernst B, Kieper WC et al (2002) Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells. J Exp Med 195:1523–1532CrossRefPubMedPubMedCentral
25.
Coleman S, Clayton A, Mason MD et al (2005) Recovery of CD8+ T-cell function during systemic chemotherapy in advanced ovarian cancer. Cancer Res 65:7000–7006CrossRefPubMed
26.
Bellone G, Novarino A, Vizio B et al (2009) Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy. Int J Oncol 34:1701–1715CrossRefPubMed
27.
Lissoni P, Brivio F, Fumagalli L et al (2005) Enhancement of the efficacy of chemotherapy with oxaliplatin plus 5-fluorouracil by pretreatment with il-2 subcutaneous immunotherapy in metastatic colorectal cancer patients with lymphocytopenia prior to therapy. In Vivo 19:1077–1080PubMed
Metadata
Title
Prognostic Significance of Lymphocyte Counts in Colon Cancer Patients Treated with FOLFOX Chemotherapy
Authors
O Kyu Noh
Seung Yeop Oh
Young Bae Kim
Kwang Wook Suh
Publication date
01-11-2017
Publisher
Springer International Publishing
Published in
World Journal of Surgery / Issue 11/2017
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-017-4104-6